Free Trial

Apogee Therapeutics (NASDAQ:APGE) Announces Earnings Results, Misses Estimates By $0.25 EPS

Apogee Therapeutics logo with Medical background
Remove Ads

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.25), Zacks reports.

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE traded up $4.01 during midday trading on Thursday, hitting $35.44. 1,063,354 shares of the company's stock were exchanged, compared to its average volume of 574,500. The firm's fifty day simple moving average is $39.35 and its 200-day simple moving average is $47.10. The company has a market cap of $1.60 billion, a PE ratio of -14.64 and a beta of 2.46. Apogee Therapeutics has a twelve month low of $29.10 and a twelve month high of $72.29.

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 4,540 shares of the company's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total value of $221,370.40. Following the completion of the transaction, the insider now owns 258,073 shares in the company, valued at $12,583,639.48. This represents a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $40.58, for a total value of $608,700.00. Following the sale, the chief executive officer now owns 1,302,987 shares in the company, valued at $52,875,212.46. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,145 shares of company stock valued at $1,897,799 over the last three months. 36.10% of the stock is owned by corporate insiders.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages recently weighed in on APGE. Wedbush reaffirmed an "outperform" rating and set a $90.00 target price on shares of Apogee Therapeutics in a research note on Monday. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a "buy" rating and a $89.00 target price for the company. Finally, Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a "buy" rating and a $89.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics has a consensus rating of "Buy" and a consensus price target of $88.83.

Get Our Latest Stock Analysis on APGE

About Apogee Therapeutics

(Get Free Report)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Recommended Stories

Earnings History for Apogee Therapeutics (NASDAQ:APGE)

Should You Invest $1,000 in Apogee Therapeutics Right Now?

Before you consider Apogee Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.

While Apogee Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads